PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey
- PMID: 29871906
- DOI: 10.1158/1078-0432.CCR-18-1314
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey
Abstract
PARP inhibitors have transformed treatment for ovarian cancer, a cancer notable for homologous recombination (HR) deficiencies and aberrant DNA repair, especially in the high-grade serous subtype. PARP inhibitors are now approved for recurrent ovarian cancer as maintenance following response to platinum chemotherapy and BRCA-mutated (BRCAm) cancer treatment. Clin Cancer Res; 24(17); 4062-5. ©2018 AACRSee related article by Ison et al., p. 4066.
©2018 American Association for Cancer Research.
Comment on
-
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.Clin Cancer Res. 2018 Sep 1;24(17):4066-4071. doi: 10.1158/1078-0432.CCR-18-0042. Epub 2018 Apr 12. Clin Cancer Res. 2018. PMID: 29650751
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources